<DOC>
	<DOCNO>NCT02964078</DOCNO>
	<brief_summary>The main purpose study evaluate effect interleukin-2 give combination pembrolizumab . Interleukin-2 ( IL-2 ) also call aldesleukin , Proleukin™ . Pembrolizumab also call Keytruda™ , anti-PD-1 antibody .</brief_summary>
	<brief_title>Interleukin-2 Pembrolizumab Metastatic Kidney Cancer</brief_title>
	<detailed_description>The treatment organize block 9 week , pembrolizumab treatment plan week 1 , 4 7 . On second third block , interleukin-2 add , 5 dos time , one dose every 8 hour , weekly schedule two week week 1 week 4 pembrolizumab dos . There dose escalation portion : The dose schedule IL-2 fix , 600,000 IU/kg/dose , cap 66 mIU/dose . Doses may omit safety . The dose pembrolizumab fix , flat dose 200 mg/dose .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Diagnosis/Condition Entry Trial : Metastatic kidney cancer . Clear cell histology component primary metastatic lesion . Willing able provide write informed consent trial . Age 18 day signing inform consent . Have measurable disease base Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 . Willing provide tissue newly obtain archival tissue , available . Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale . Demonstrate adequate organ function , screen lab perform within 10 day treatment initiation . Females childbearing potential must negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . Females childbearing potential must agree use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Males must agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . Cardiac test either exercise stress test thallium stress test , within 3 month start first treatment day . Atrial fibrillation rate control allow . Note first treatment day 9 week first IL2 treatment day . If cardiologist 's evaluation determine superfluous base assessment , may omit . Pulmonary function test require , within 3 month start . The treat physician ass suitability usual clinical criterion use IL2 treatment generally consistent Proleukin™ prescribe information . There specific minimum result specify protocol . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose treatment . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . Has know history active Bacillus Tuberculosis ( TB ) . Has hypersensitivity pembrolizumab excipients . The number prior therapy restrict follow : ( ) Zero one prior therapy precede one year . This serve limit treatment cohort patient either slowly progressive disease , one prior therapy . ( b ) No prior PD1 PDL1 antibody therapy allow . ( c ) Prior IL2 allow , finish 1 year prior . ( ) The follow count medical therapy : nephrectomy , radiation therapy , energyablative technique , metastasectomy . Has prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . Note : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Potential participant previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . This exception include carcinomatous meningitis exclude regardless clinical stability . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( e.g. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment would exclusionary . Has know history , evidence active , noninfectious pneumonitis . Has active infection require systemic therapy . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere participation full duration trial , best interest patient participate , opinion treat investigator . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , hepatitis C virus ( HCV ) RNA [ qualitative ] detect ) . Has receive live vaccine within 30 day plan start study therapy . Note : Seasonal influenza vaccine injection generally inactivate flu vaccine allow ; however intranasal influenza vaccine ( e.g. , FluMist® ) live attenuate vaccine , allow . Myocardial infarction , stroke , coronary artery bypass surgery , coronary stent , unstable angina within one year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Kidney Disease</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Antibody</keyword>
</DOC>